HCPCS Level II code J9019 represents the injectable antineoplastic agent asparaginase (erwinaze), billed per 1,000 IU unit. The code is used when this drug is supplied and administered in clinical settings that deliver parenteral oncology therapies. Nationally, biologic and chemotherapy drug billing codes like J9019 are important for tracking utilization, payer coverage, and cost management for high-cost specialty medications.

This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and common sites of service, plus guidance on the types of benchmarks and policy metrics typically associated with drug J-codes: utilization units, site-of-service distribution, and payer coverage patterns. Where available, the publication summarizes typical modifiers and billing considerations related to specialty drug administration.

The report is intended to inform billing managers, revenue cycle staff, and policy analysts about the role of J9019 in oncology drug billing, what to expect in payer negotiations, and which operational metrics are relevant for monitoring drug administration and reimbursement. Data not available in the input will be noted as such in relevant sections.